| | Family Health | Women's Health
Female Pattern Hair Loss (Androgenetic Alopecia): Diagnosis, Treatments & Outlook
Female pattern hair loss (FPHL), or androgenetic alopecia, affects ~40% of women by age 50. Unlike male pattern baldness, it presents as diffuse central thinning with preserved frontal hairline.
Clinical Presentation
- Ludwig Classification: Type I (mild, central thinning), Type II (moderate, widened part), Type III (severe, near-total vertex loss).
- Sinclair Scale: 5-stage photographic guide for clinical tracking.
- Frontal hairline usually maintained; no vertex balding like men.
Pathophysiology
- Genetic: Polygenic; androgen receptor (AR), aromatase (CYP19A1), Wnt/β-catenin pathway genes.
- Hormonal: DHT (from testosterone via 5α-reductase) miniaturizes follicles in genetically susceptible women. Androgens may be normal; follicular sensitivity is key.
- Contributing factors: PCOS, menopause (estrogen decline unmasks androgens), thyroid dysfunction, iron deficiency, medications (androgenic progestins, valproate).
Diagnostic Workup
- History: onset, pattern, family history, menstrual cycle, medications.
- Scalp exam: trichoscopy (diversity of hair diameters, peripilar signs, yellow dots).
- Labs if indicated: CBC, ferritin, TSH, free/total testosterone, DHEAS, prolactin (rule out hyperandrogenism).
Evidence-Based Treatments
FDA-Approved / First-Line
- Topical minoxidil 2% (women) / 5% (off-label): Prolongs anagen, increases follicular size. 40–60% show stabilization/regrowth at 12 months. Shedding at 2–8 weeks = good sign.
- Oral minoxidil 0.25–1.25 mg/day: Emerging off-label use; superior adherence, efficacy; monitor for hypertrichosis, edema, tachycardia.
Anti-Androgens (Off-Label, Require Contraception)
- Spironolactone 50–200 mg/day: Aldosterone antagonist + androgen receptor blockade. First-line for hyperandrogenism/PCOS.
- Finasteride 1–2.5 mg/day (postmenopausal): 5α-reductase type II inhibitor. Teratogenic (Category X).
- Dutasteride 0.5 mg/day: Dual 5α-reductase inhibitor; more potent.
- Cyproterone acetate (combined OCP): Androgen receptor antagonist + gonadotropin suppression.
Adjunctive / Emerging
- Low-level laser therapy (LLLT): FDA-cleared devices (combs, helmets); modest evidence for density increase.
- Platelet-rich plasma (PRP): Growth factors; multiple sessions; variable protocols.
- Microneedling + minoxidil: Enhanced delivery.
- Hair transplantation: FUE/FUT for stable donor area; artistic design critical for diffuse pattern.
Prognosis & Monitoring
- Chronic, progressive without treatment.
- Response assessed at 6–12 months (global photography, trichoscopy, hair mass index).
- Maintenance therapy lifelong; discontinuation → reversal in 3–6 months.
- Psychosocial support: significant QoL impact; refer to support groups (NAAF, Alopecia UK).
Women's Health - Related Articles
- Transferring Ownership of a Bodybugg: A Complete Guide
- Fertility Massage Certification: Enhance Your Practice & Help Couples Conceive
- Preventing Yeast Infections: Reduce Your Risk & Stay Healthy
- Understanding Blue Moles on the Face: Causes & Appearance
- Ovarian Cysts: Symptoms, Causes & When to See a Doctor | Mayo Clinic
- Removing a Tampon Without a String: A Step-by-Step Guide
- Vaginal Hysterectomy: Benefits, Recovery, and Procedure
